Yale University and Genaissance Pharmaceuticals Co-Sponsor Conference on Pharmacogenetics: "From Concept to Reality"

Scientist and government officials will speak at Yale University School of Medicine April 3 during the Fourth Annual Genaissance Pharmacogenetics and Medicine Lectures.

Scientist and government officials will speak at Yale University School of Medicine April 3 during the Fourth Annual Genaissance Pharmacogenetics and Medicine Lectures.

The purpose of the meeting is to provide an update on the scientific, medical, regulatory, economic and ethical perspectives of “personalized medicine,” which involves tailoring medication to a patient’s genetic makeup.

The symposium will be held from 8:30 a.m. to 1 p.m. in Yale’s Harkness Auditorium at the Sterling Hall of Medicine, 333 Cedar St., New Haven.

Speakers and topics include:

–Gail Wilensky, senior fellow, Center for Health Affairs/Project HOPE, chair, Medicine Payment Advisory Commission, “The Potential Impact of Pharmacogenetics on the Healthcare Economy.”

–Michael Waldholz, editor, Health and Science Group, The Wall Street Journal, “Expectations of Personalized Healthcare: Consumer Awareness and Educational Needs.”

–David Feigal, M.D., Center for Devices and Radiological Health, Food and Drug Administration, “Drug Development, Regulation and Genetically-Guided Therapy.”

–Ralph Horwitz, M.D., chair, Internal Medicine, professor of Internal Medicine and Epidemiology, Yale University School of Medicine, “Population Medicine vs Individual Health: The Promise of Pharmacogenetics.”

–Robert Levine, M.D., professor of medicine, lecturer in pharmacology, Yale University School of Medicine, “The Ethical Implications of Personalized Medicine.”

–Gualberto Ruano, M.D., chief executive officer, Genaissance Pharmaceuticals, Inc., “Pharmacogenetics: A Look at 21st Century Medicine.”

Genaissance Pharmaceuticals, Inc. applies population genomics, informatics and clinical data to the development of personalized medicines. Genaissance discovers proprietary haplotypes, which are genomic markers, that are predictive of drug response based on each patient’s DNA.

For further information about Genaissance please contact Anita Kaul at 203-786-3439 or a.kaul@genaissance.com. For registration information, please call Deborah Lewis at 203-786-3528 or register on line at www.genaissance.com

Share this with Facebook Share this with X Share this with LinkedIn Share this with Email Print this

Media Contact

Office of Public Affairs & Communications: opac@yale.edu, 203-432-1345